STAR Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,195 Cr
verified against source
Revenue YoY
3.6%
reported change
EBITDA
₹236 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Strides Pharma delivered a mixed Q3 FY26 with ₹236 crore EBITDA (up 12% YoY, highest ever quarterly) and ₹128 crore operational PAT (up 39%), driven by gross margin expansion to ~60% and strong XUS market performance at $64 million (up 20% YoY). However, overall revenue growth was muted at 3.6% due to institutional business weakness—excluding institutional, growth was 8.6-9%. US revenues remained flat at $70 million impacted by delayed flu season, new competition in key products, and slower KOTA allocations. Management reiterated $400 million US target by FY28 and plans to mirror US with XUS markets in two years. Balance sheet improved with Net Debt/EBITDA at 1.59x (from 1.9x in FY25). ROCE improved to 15.8%. Key risks include US market concentration, seasonal volatility, and foreign exchange impact on rupee-denominated debt. Management appointed Peter Hardwick as North American CEO to drive US turnaround.
Colored figures show movement against the previous available record.
Guidance to track
- Company reiterated medium-term target for US market despite current quarter weakness; growth to be driven by 60+ products in pipeline, control substances normalization, and relaunches from dormant portfolio.
- XUS markets (other regulated + growth markets) aimed to reach parity with US revenues within two years; currently running $64M quarterly vs US at $70M with gap narrowing to ~$6M.
- Management indicated sustainable gross margin range of 58-60% going forward, with current quarter at 61% driven by favorable business mix and reduced institutional business.
- Maintenance capex expected in ₹100-125 crore range annually; additional opportunistic investments for global product rights (both US and XUS markets) not quantified.
Risks flagged
- Q3 flu season did not materialize as expected (only played out in last few days of December), unlike prior years when Q3 and Q4 delivered strong seasonal sales. This pattern may repeat and impact US revenue targets.
- Donor funding from organizations like Global Fund has reduced significantly as several countries cut contributions. While some countries are adding to their contributions, the gap remains very large to fill, keeping institutional revenue muted.
- Control substances require a full year of operational track record to demonstrate manufacturing capability and earn more KOTA allocations. Management expects this cycle to complete in next 2-3 months, with FY27 expected to be 'fairly better' for this segment.
- New competitors entered couple of key products where Strides held strong market share and had good runs for last few years. Management acknowledged competition will always be present but characterized it as select molecule-specific rather than portfolio-wide.
Key quotes
- 3.6% increase in revenue resulted in 8 plus percentage increase in gross margins plus the 12% increase in EBITDA and almost 38% increase in PAT. The multiple multiplier effect is very very visible in the financials.
- The growth will be led by many levers which are all part of this as far as the US is concerned we have got number of dominant products the control substances should pan out quite well for us in the near term.
- Our endeavor is to get a very diversified company and if you see the gap between the non US and the XUS and the US it's come down to almost about 50 crore the difference in the revenue for the quarter.
Research modules